Societal Impact Statement Therapeutic protein production in plants is an area of great
potential for increasing and improving the production of proteins for the treatment or …

The manufacturing of recombinant protein is traditionally divided in two main steps:
upstream (cell culture and synthesis of the target protein) and downstream (purification and …

Chinese hamster ovary (CHO)–derived cell lines are the preferred host cells for the
production of therapeutic proteins. Here we present a draft genomic sequence of the CHO …

Abstract Adoption of Quality by Design (QbD) principles, regulatory support of QbD, process
analytical technology (PAT), and continuous manufacturing are major factors effecting new …

Antibodies are well established in mainstream clinical practice and present an exciting area
for collaborative research and development in industry and academia alike. In this review …

The demand for production of glycoproteins from mammalian cell culture continues with an
increased number of approvals as biopharmaceuticals for the treatment of unmet medical …

Sales of monoclonal antibody (mAbs) therapies exceeded
40billionin2010andareexpectedtoreach 70 billion by 2015. The majority of the approved …

Cell-free protein synthesis (CFPS) represents a promising technology for efficient protein
production targeting especially so called “difficult-to-express” proteins whose synthesis is …

The ability to efficiently produce recombinant proteins in a secreted form is highly desirable
and cultured mammalian cells such as CHO cells have become the preferred host as they …

To complement the recent genomic sequencing of Chinese hamster ovary (CHO) cells,
proteomic analysis was performed on CHO cells including the cellular proteome, secretome …